UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 182

Sortiert nach

PD-1 Pathway Inhibitors: Immuno-Oncology Agents for Restoring Antitumor Immune Responses

Pharmacotherapy, 2016-03, Vol.36 (3), p.317-334

2016

Volltextzugriff (PDF)

Targeting the PD-1 pathway in pediatric solid tumors and brain tumors

OncoTargets and therapy, 2017-01, Vol.10, p.2097-2106

2017

Volltextzugriff (PDF)

Sunitinib Malate for the Treatment of Metastatic Renal Cell Carcinoma and Gastrointestinal Stromal Tumors

Clinical therapeutics, 2007-07, Vol.29 (7), p.1338-1353

2007

Volltextzugriff (PDF)

Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings

Journal of Oncology Pharmacy Practice, 2020-09, Vol.26 (6), p.1461-1474

2020

Volltextzugriff (PDF)

Vena Cava Filter Retrieval Rates and Factors Associated With Retrieval in a Large US Cohort

Journal of the American Heart Association, 2017-09, Vol.6 (9), p.n/a

2017

Volltextzugriff (PDF)

Doxorubicin and Paclitaxel-Loaded Lipid-Based Nanoparticles Overcome Multidrug Resistance by Inhibiting P-Glycoprotein and Depleting ATP

Cancer research (Chicago, Ill.), 2009-05, Vol.69 (9), p.3918-3926

2009

Volltextzugriff (PDF)

Sticky Issues: What APs Need to Know About Anticoagulants and Patients With Cancer

Journal of the advanced practitioner in oncology, 2021-04, Vol.12 (3), p.262-265

2021

Volltextzugriff (PDF)

Age Adjusted Comorbidity Risk Index Does Not Predict Outcomes in an Autologous Hematopoietic Stem Cell Transplant Population

Cell transplantation, 2022-02, Vol.31, p.9636897221080385-9636897221080385

2022

Volltextzugriff (PDF)

Statin use and venous thromboembolism in cancer: A large, active comparator, propensity score matched cohort study

Thrombosis research, 2017-10, Vol.158, p.49-58

2017

Volltextzugriff (PDF)

Development of new lipid-based paclitaxel nanoparticles using sequential simplex optimization

European journal of pharmaceutics and biopharmaceutics, 2009-05, Vol.72 (1), p.9-17

2009

Volltextzugriff (PDF)

Pharmacokinetics of Intravenous Levofloxacin Administered at 750 Milligrams in Obese Adults

Antimicrobial Agents and Chemotherapy, 2011-07, Vol.55 (7), p.3240-3243

2011

Volltextzugriff (PDF)

Incidence and Risk Factors of Thromboembolism with Multiple Myeloma in the Presence of Death as a Competing Risk: An Empirical Comparison of Statistical Methodologies

Healthcare (Basel), 2016-02, Vol.4 (1), p.16

2016

Volltextzugriff (PDF)

Association of hypertension and treatment outcomes in advanced stage non-small cell lung cancer patients treated with bevacizumab or non-bevacizumab containing regimens

Journal of oncology pharmacy practice, 2018-04, Vol.24 (3), p.209-217

2018

Volltextzugriff (PDF)

Optimizing postgraduate year 3 training

American journal of health-system pharmacy, 2014-11, Vol.71 (22), p.1924-1925

2014

Volltextzugriff (PDF)

Impact of Time-Varying Treatment Exposures on the Risk of Venous Thromboembolism in Multiple Myeloma

Healthcare (Basel), 2016-12, Vol.4 (4), p.93

2016

Volltextzugriff (PDF)

Association of time to antibiotics and clinical outcomes in adult hematologic malignancy patients with febrile neutropenia

Journal of oncology pharmacy practice, 2017-06, Vol.23 (4), p.278-283

2017

Volltextzugriff (PDF)

Capecitabine-induced ventricular fibrillation arrest: Possible Kounis syndrome

Journal of oncology pharmacy practice, 2016-04, Vol.22 (2), p.335-340

2016

Volltextzugriff (PDF)

The Reversal of Inhibitors in Congenital Hemophilia

Pharmacotherapy, 2013-02, Vol.33 (2), p.157-164

2013

Volltextzugriff (PDF)

Histological and genetic markers for non-small-cell lung cancer: Customizing treatment based on individual tumor biology

American journal of health-system pharmacy, 2010-01, Vol.67 (1 Supplement 1), p.S3-S9

2010

Volltextzugriff (PDF)

Concurrent Everolimus With Hepatic Transarterial Bland Embolotherapy in Patients With Metastatic Well-Differentiated Neuroendocrine Tumors

Oncology (Williston Park, N.Y.), 2020-11, Vol.34 (11), p.471

2020

Volltextzugriff (PDF)

Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects

Investigational new drugs, 2005-01, Vol.23 (1), p.39-49

2005

Volltextzugriff (PDF)

Use of histological and genetic markers in optimizing therapy for patients with non-small-cell lung cancer: introduction

American journal of health-system pharmacy, 2010-01, Vol.67 (1), p.S1

2010

Volltextzugriff (PDF)

Inactivation of the Ketoreductase gilU Gene of the Gilvocarcin Biosynthetic Gene Cluster Yields New Analogues with Partly Improved Biological Activity

Chembiochem : a European journal of chemical biology, 2009-01, Vol.10 (2), p.278-286

2009

Volltextzugriff (PDF)

Evolving role of antineoplastic agents in colorectal cancer

American journal of health-system pharmacy, 2006-05, Vol.63 (9 Supplement 2), p.S4-S11

Adams, Val R

2006

Volltextzugriff (PDF)

Cytotoxic Activities of New Jadomycin Derivatives

Journal of antibiotics, 2005-06, Vol.58 (6), p.405-408

2005

Volltextzugriff (PDF)

1 – 25 von 182

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieTime Canada

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(84)
Mit Volltextzugriff
(166)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(58)
Life Sciences & Biomedicine
(55)
Humans
(47)
Pharmacology & Pharmacy
(26)
Biological And Medical Sciences
(21)
Medical Sciences
(21)
Male
(20)
Female
(19)
Oncology
(17)
Middle Aged
(14)
Adult
(10)
Cancer
(10)
Pharmacology. Drug Treatments
(9)
Chemotherapy
(8)
Aged
(7)
Antineoplastic Agents - Adverse Effects
(7)
Cancer Therapies
(7)
Cell Line, Tumor
(7)
Metastasis
(7)
Patients
(7)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

PD-1 Pathway Inhibitors: Immuno-Oncology Agents for Restoring Antitumor Immune Responses

Targeting the PD-1 pathway in pediatric solid tumors and brain tumors

Sunitinib Malate for the Treatment of Metastatic Renal Cell Carcinoma and Gastrointestinal Stromal Tumors

Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings

Vena Cava Filter Retrieval Rates and Factors Associated With Retrieval in a Large US Cohort

Doxorubicin and Paclitaxel-Loaded Lipid-Based Nanoparticles Overcome Multidrug Resistance by Inhibiting P-Glycoprotein and Depleting ATP

Sticky Issues: What APs Need to Know About Anticoagulants and Patients With Cancer

Age Adjusted Comorbidity Risk Index Does Not Predict Outcomes in an Autologous Hematopoietic Stem Cell Transplant Population

Statin use and venous thromboembolism in cancer: A large, active comparator, propensity score matched cohort study

Development of new lipid-based paclitaxel nanoparticles using sequential simplex optimization

Pharmacokinetics of Intravenous Levofloxacin Administered at 750 Milligrams in Obese Adults

Incidence and Risk Factors of Thromboembolism with Multiple Myeloma in the Presence of Death as a Competing Risk: An Empirical Comparison of Statistical Methodologies

Association of hypertension and treatment outcomes in advanced stage non-small cell lung cancer patients treated with bevacizumab or non-bevacizumab containing regimens

Optimizing postgraduate year 3 training

Impact of Time-Varying Treatment Exposures on the Risk of Venous Thromboembolism in Multiple Myeloma

Association of time to antibiotics and clinical outcomes in adult hematologic malignancy patients with febrile neutropenia

Capecitabine-induced ventricular fibrillation arrest: Possible Kounis syndrome

The Reversal of Inhibitors in Congenital Hemophilia

Histological and genetic markers for non-small-cell lung cancer: Customizing treatment based on individual tumor biology

Concurrent Everolimus With Hepatic Transarterial Bland Embolotherapy in Patients With Metastatic Well-Differentiated Neuroendocrine Tumors

Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects

Use of histological and genetic markers in optimizing therapy for patients with non-small-cell lung cancer: introduction

Inactivation of the Ketoreductase gilU Gene of the Gilvocarcin Biosynthetic Gene Cluster Yields New Analogues with Partly Improved Biological Activity

Evolving role of antineoplastic agents in colorectal cancer

Cytotoxic Activities of New Jadomycin Derivatives

Aktive Filter

Suchergebnisse filtern